Navigation Links
Wise Sky Highlights Their Disappointment at Emergent's Decision Not to Enter the China Market

Wise Sky Highlights Their Disappointment at Emergent's Decision Not to Enter the China Market -- SHANGHAI, Sept. 2 /PRNewswire-Asia/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, Legal Issues Click to view news release full screen  

Wise Sky Highlights Their Disappointment at Emergent's Decision Not to Enter the China Market


Wise Sky (Hong Kong) Limited Suffers Due to Last Minute Pull-out

SHANGHAI, Sept. 2 /PRNewswire-Asia/ -- Wise Sky (Hong Kong) Limited today announced its disappoint at the recent decision made by Emergent BioSolutions not to enter the China market. Wise Sky conducted product promotions and sales of BioThrax, a vaccine produced by Emergent BioSolutions, under the terms of an agreement signed with Emergent BioSolutions on June 3, 2009, and is therefore disappointed and concerned by Emergent BioSolution's decision to not enter the Mainland China market despite having an agreement in place with Wise Sky.

Emergent BioSolutions is a NASDAQ listed company famous for the production of BioThrax, the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. In early 2009, Emergent made clear their decision to enter Asian markets including Mainland China, one of the biggest markets concerned. The vice presidents and other important managers of Emergent then visited China several times, attending meetings and conferences with medicine experts, getting the chance to exchange their thoughts and ideas with China's top professionals and government officers, as a result of efforts and arrangements undertaken by Wise Sky (Hong Kong) Limited. In May 2009, Emergent and Wise Sky signed an exclusive marketing agreement. According to this agreement, Emergent agreed to authorize Wise Sky to sell BioThrax as its representative within the territory of Mainland China.

In China, the major clients for anti-terrorism products are the government authorities, government-funded special departments and the armed forces. Due to the importance of importing the anti-terrorism products, the whole administrative procedure for market entrance is complicated and time-consuming, especially for the vaccine products that require the approval of, and registration in, China's State Food and Drug Administration ("SFDA"). Wise Sky is a professional trading agent who has wide government connections and lots of experience in the sale of medicines and anti-terrorism products. Taking advantage of the good relationship with the government, Wise Sky sought purchasers all around China and successfully reached preliminary purchase intentions with several buyers such as the Bureau of Shanghai World Expo Coordination and the Shanghai Municipal Center for Disease Control and Prevention ("SCDC"). Also, Wise Sky was actively negotiating with the government, trying to expedite the approval process for BioThrax. However, after a long time of waiting and internal discussions, Emergent finally decided against filing BioThrax with the SFDA in early 2010, which ultimately cancelled the marketing agreement, as sales and promotions could not continue. Wise Sky also received a formal letter from Emergent terminating the marketing agreement without any compensation. The letter was dated April 26, 2010.

Wise Sky understands Emergent's decision to not enter the Mainland China market is their own business decision. However, in addition to the loss of orders, commissions and promotion expenses, Wise Sky strongly believes that Emergent's decision damages the name of Wise Sky, in a more profound way, by causing a loss of goodwill in China and jeopardizing the relationship between Wise Sky and China's governing authorities, which Wise Sky spent years to establish and maintain. Wise Sky believes this turn of events will have a negative influence and will further affect the marketing of other anti- terrorism products represented by Wise Sky in Mainland China. Wise Sky extends its disappointment at Emergent's decision not to enter the china market.

SOURCE Wise Sky (Hong Kong) Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
Breaking Medicine Technology:
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios ... titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new ... any font, giving users limitless opportunities to stylize and create designs quickly and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
(Date:11/25/2015)... ... 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna ... and far-infrared saunas. , For traditional saunas, Finnleo is offering 20% ... wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown ...
Breaking Medicine News(10 mins):